We are using cookies in order to offer you the most relevant information. We have published
new Cookie Policy which you should read to find out more. more
Please accept cookies for optimal performance.

Cardio-HART™, a Breakthrough Heart Diagnostic device is CE Marked, just in time to address Europe’s Pandemic consequences of COVID-19.

Just in time to meet the consequences of COVID-19 caused heart disease, CHART has obtained CE Mark certification for use in the EU. 

With Europe’s vaunted medical systems strained to a breakpoint as a result of COVID-19, they are faced with double jeopardy: first, re-initializing how they deliver primary care services; and second, how to deal with the legacy of COVID-19 induced heart disease. Whatever the strategy, telemedicine will play a central role in ensuring ongoing access to basic medical services, redefining Primary Care forever.

Telemedicine is the future of patient visits to the doctor, but especially in this pandemic as it helps maintain social distancing safety guidelines. This will be critical in the face of the feared second-wave of COVID-19. Healthcare systems, slow to move to telemedicine before the pandemic, have dropped all pretense of caution as social distancing through telemedicine makes healthcare workers safer, without being any less effective for the patient, is now the main model for Primary Care.

With the initial threat of COVID-19 mitigated, the pandemic legacy of COVID-19 induced heart disease will ravage symptomatic COVID-19 patients leading to increased heart disease-related morbidity, and this for years to come. As if not enough, many COVID-19 asymptomatic and mild-symptomatic, patients could have also been exposed to its legacy of heart disease, which could yet manifest itself in a widespread epidemic of COVID-19 induced heart disease.

CHART is Cardiac-Telemedicine™ at its best, transforming Primary care into the new front line of heart care, to meet the post-pandemic needs of all Europeans. 

Post-Pandemic Cardiac-Telemedicine™.

The divide between Primary Care and Cardiology Care, the next level of care, was always a major unmet medical need, tolerated only because of a lack of an effective, easy to use, medical device that could help bridge the gap. At 44%, the traditional ECG/EKG devices were simply never sufficiently effective pre-pandemic and will be virtually useless in a post-pandemic telemedicine environment.

Effective Cardiac-Telemedicine™ has two main conditions: First, it must support Telemedicine, allowing the physician to easily access a patients heart diagnostic test online, and understand it; and, second, it has to be highly effective, providing comprehensive diagnostic information on the patient’s condition, far beyond that of the traditional pre-Pandemic ECG/EKG devices.

Our solution for Cardiac-Telemedicine™ is…

 

Cardio-HART™ (a.k.a. “CHART”)

Known under the acronym of CHART, short for Cardio-HART™, the newly CE marked system combines a device for capturing heart physiological bio-signals and a cloud-based AI-Powered diagnostic engine. Together, they can respect social-distancing, whilst ensuring heart diagnostic effectiveness for cardiac telemedicine.

CHART goes beyond the 44% limitations of traditional ECG/EKG... complementing and augmenting its capabilities, able to detect and diagnose up to 95% of all common heart diseases, by prevalence typically found in Primary Care situations without changing the Standard of Care

CHART can detect and diagnose diseases normally only detected by Echocardiography (heart ultrasound), including LVH, DCM, AS, MS to name but a few. Detected in Primary Care, they help the telemedicine GP, identify patients that need to be referred to the cardiologist for confirmation as these are serious heart diseases that sadly, will likely be more prevalent, a legacy of COVID-19. CHART does not replace the cardiologists, it only makes the Telemedicine GP more effective.

CHART will help ensure that affected patients are not be left behind, forgotten, and neglected in the shadow of COVID-19, or its dreaded second wave.

Detected early and repeated often because it is so cost-effective, Cardiac-Telemedicine™ can ensure that the morbidity associated with the pandemic induced heart disease is first identified, then easily followed-up, well into the patient’s future. Detection is the first step in treatment.

In a recent clinical study, conducted on over 500 patients, GP’s increased their diagnostic effectiveness by some 250% over the most advanced traditional ECG/EKG systems. This resulted in a 24% reduction in FN and a 14% reduction in FP. These are numbers that GP’s in Telemedicine need, to fight the legacy of COVID-19 induced heart disease, and reduce the burden on a re-building healthcare system.   

Preparing for the future and the dreaded 2nd wave.

And with a much dreaded second imminent wave of COVID-19, heart disease needs to be detected earlier and faster to help mitigate the long-term morbidity potential and ongoing healthcare system costs that could threaten to undermine the effectiveness and access of Europe’s health-care systems. 

Europe’s newest CE Marked device, is obtained just in time to transform the nature of primary care and prepare for the future.

Comments (0)

*your email will not be published

No comments.